for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dare Bioscience Inc

DARE.OQ

Latest Trade

0.85USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.61

 - 

3.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.85
Open
--
Volume
--
3M AVG Volume
2.55
Today's High
--
Today's Low
--
52 Week High
3.25
52 Week Low
0.61
Shares Out (MIL)
16.68
Market Cap (MIL)
14.18
Forward P/E
-0.90
Dividend (Yield %)
--

Next Event

Q3 2019 Dare Bioscience Inc Earnings Release

Latest Developments

More

Dare Bioscience Says Qtrly Loss Per Share $0.29

Daré Announces Presentation Of Positive Clinical Findings For Vaginal Administration Of Novel Formulation Of Clindamycin Phosphate

Daré Bioscience Appoints William Rastetter As Chairman Of Its Board Of Directors

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dare Bioscience Inc

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Industry

Biotechnology & Drugs

Contact Info

3655 Nobel Dr Ste 260

+1.858.9267655

https://www.darebioscience.com/

Executive Leadership

William H. Rastetter

Independent Chairman of the Board

Sabrina Martucci Johnson

President, Chief Executive Officer, Secretary, Director

Gregg D. Beloff

Principal Financial Officer

Lisa Walters-Hoffert

Chief Financial Officer

Jame O'Neill

Principal Accounting Officer, Controller, Assistant Treasurer

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-14.200

2018

-1.570

2019(E)

-0.943
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.91
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-142.76
Return on Equity (TTM)
-120.47

Latest News

BRIEF-Daré Bioscience Appoints John Fair To Chief Business Officer

* DARÉ BIOSCIENCE, INC. EXPANDS LEADERSHIP TEAM, APPOINTING JOHN FAIR TO CHIEF BUSINESS OFFICER Source text for Eikon: Further company coverage:

BRIEF-Daré Bioscience Enters Into Agreement To Acquire Product To Address Vulvar And Vaginal Atrophy In Hormone Receptor-Positive Breast Cancer Patients

* DARÉ BIOSCIENCE, INC. ENTERS INTO AGREEMENT TO ACQUIRE PRODUCT TO ADDRESS VULVAR AND VAGINAL ATROPHY IN HORMONE RECEPTOR-POSITIVE BREAST CANCER PATIENTS

BRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform

* DARÉ BIOSCIENCE, INC. ENTERS INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR JUNIPER PHARMACEUTICALS’ INTRAVAGINAL RING (IVR) TECHNOLOGY PLATFORM

BRIEF-Dare Bioscience Says Board Increased Size To 6 Directors

* DARE BIOSCIENCE - ON APRIL 9, BOARD INCREASED SIZE OF BOARD FROM 5 DIRECTORS TO 6 DIRECTORS , ELECTED JESSICA GROSSMAN TO FILL VACANCY - SEC FILING Source: (https://bit.ly/2v7rEnA) Further company coverage:

BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil

* DARÉ BIOSCIENCE, INC. REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Dare Bioscience Announces Development And Option Agreement With Orbis Biosciences For Long-Acting Injectable Contraceptive

* DARÉ BIOSCIENCE ANNOUNCES EXCLUSIVE DEVELOPMENT AND OPTION AGREEMENT WITH ORBIS BIOSCIENCES FOR LONG-ACTING INJECTABLE CONTRACEPTIVE

BRIEF-Empery Asset Management Lp Reports 9.05 pct Passive Stake In Dare Bioscience As Of Feb 13

* EMPERY ASSET MANAGEMENT LP REPORTS 9.05 PERCENT PASSIVE STAKE IN DARE BIOSCIENCE INC AS OF FEB 13, 2018 - SEC FILING Source text - (http://bit.ly/2CC1wzx) Further company coverage:

BRIEF-Daré Bioscience Announces Effective License, Collaboration Deal For Topical Sildenafil

* DARÉ BIOSCIENCE, INC. ANNOUNCES EFFECTIVE LICENSE AND COLLABORATION AGREEMENT FOR TOPICAL SILDENAFIL FOR FEMALE SEXUAL AROUSAL DISORDER

BRIEF-Dare Bioscience Inc To Raise About $10.25 Mln

* DARÉ BIOSCIENCE, INC. TO RAISE APPROXIMATELY $10.25 MILLION

BRIEF-Daré Bioscience Announces Proposed Public Offering Of Common Stock

* DARÉ BIOSCIENCE, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD

* DARÉ BIOSCIENCE, INC. ENTERS INTO LICENSE AND COLLABORATION AGREEMENT FOR A PRODUCT WITH THE POTENTIAL TO RECEIVE THE FIRST FDA APPROVAL FOR FEMALE SEXUAL AROUSAL DISORDER

BRIEF-Dare Bioscience Enters Into A License Agreement With Strategic Science And Technologies

* DARE BIOSCIENCE INC - ON FEB 11, 2018, CO ENTERED INTO A LICENSE AGREEMENT WITH STRATEGIC SCIENCE AND TECHNOLOGIES-D & STRATEGIC SCIENCE TECHNOLOGIES

BRIEF-Dare Bioscience Says Entered Into Common Stock Sales Agreement

* DARE BIOSCIENCE SAYS ON JANUARY 4, 2018, CO ENTERED INTO COMMON STOCK SALES AGREEMENT - SEC FILING

BRIEF-Daré Bioscience announces MoU with CONRAD for conduct of Ovaprene postcoital test clinical trial

* Daré Bioscience, Inc announces memorandum of understanding with Conrad for the conduct of the Ovaprene® postcoital test clinical trial

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up